Blair William & Co. IL grew its position in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 7.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,580 shares of the biotechnology company’s stock after purchasing an additional 4,410 shares during the quarter. Blair William & Co. IL owned approximately 0.08% of Arrowhead Pharmaceuticals worth $1,296,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $1,142,000. Cubist Systematic Strategies LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $244,000. Northern Trust Corp boosted its stake in Arrowhead Pharmaceuticals by 380.1% during the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock worth $14,464,000 after acquiring an additional 841,982 shares in the last quarter. United Services Automobile Association boosted its stake in Arrowhead Pharmaceuticals by 69.6% during the second quarter. United Services Automobile Association now owns 19,043 shares of the biotechnology company’s stock worth $259,000 after acquiring an additional 7,816 shares in the last quarter. Finally, Swiss National Bank bought a new position in Arrowhead Pharmaceuticals during the second quarter worth $1,850,000. 63.33% of the stock is currently owned by institutional investors.

In related news, Director Douglas B. Given sold 3,000 shares of the stock in a transaction on Friday, November 23rd. The shares were sold at an average price of $12.74, for a total transaction of $38,220.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Peter Brian Leone sold 131,137 shares of the stock in a transaction on Friday, October 19th. The stock was sold at an average price of $13.49, for a total transaction of $1,769,038.13. Following the transaction, the vice president now directly owns 160,000 shares in the company, valued at $2,158,400. The disclosure for this sale can be found here. Over the last three months, insiders have sold 215,637 shares of company stock worth $2,980,043. 4.60% of the stock is owned by insiders.

Several brokerages recently issued reports on ARWR. B. Riley raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $18.00 to $19.00 in a research note on Thursday, September 6th. Chardan Capital reissued a “buy” rating and set a $17.50 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 13th. Cantor Fitzgerald increased their target price on shares of Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, October 4th. William Blair reissued an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $21.45.

Shares of NASDAQ ARWR opened at $13.13 on Friday. The firm has a market cap of $1.19 billion, a P/E ratio of -27.94 and a beta of 2.05. Arrowhead Pharmaceuticals Inc has a 12-month low of $3.01 and a 12-month high of $22.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.69 and a current ratio of 8.69.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/blair-william-co-il-has-1-30-million-stake-in-arrowhead-pharmaceuticals-inc-arwr/2669385.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Story: How Do Tariffs Affect Trade Balances?

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.